In this issue of JASN, Perl et al., compare outcomes between PD and HD among a Canadian cohort of incident ESRD patients, with the HD patients stratified by dialysis access. The authors speculate that patients initiating HD with an arteriovenous fistula or graft (AVF/AVG) versus a catheter would be more similar to patients starting dialysis with a PD catheter, thus minimizing selection bias. They also hypothesize that the previously identified early survival advantage associated with PD versus HD would be attenuated in a comparison that controlled for vascular access. This study included 38,512 patients incident to dialysis between 2001 and 2008 who were registered in the Canadian Organ Replacement Register. Approximately 19% of patients started PD, and, of those who started on HD, only 21.4% initiated dialysis with an AVF or AVG. Similar to prior studies, PD patients in this cohort had lower overall comorbidity compared with HD patients, including a lower prevalence of diabetes mellitus, coronary artery disease, peripheral vascular disease, malignancy, and pulmonary disease.

Overall, 1-yr adjusted mortality was higher with HD compared with PD; however, when patients were stratified by dialysis access type, the increased mortality was limited to HD patients with a catheter. Among patients who started HD with an AVF/AVG versus PD, 1-yr adjusted mortality was equivalent between HD and PD (hazard ratio 0.9, 95% CI 0.8 to 1.1). However, 5-yr adjusted mortality was lower among HD patients with an AVF/AVG relative to PD patients (HR 0.80, 95% CI 0.80 to 0.90). Among patients who started HD with a catheter versus PD, 1-yr and 5-yr adjusted mortality was higher among HD-catheter patients versus PD patients. However, after the first year, HD-catheter patients had similar mortality risk to PD patients.

In further sensitivity analyses including the use of marginal structures models, which adjusted for propensity scores for selection of dialysis modality and probability of renal transplantation, the results were robust. In prespecified subgroup analyses, nearly all subgroups had improved 5-yr survival associated with HD with an AVG/AVF versus PD, while there was decreased survival among those with HD with a catheter versus PD.

These findings provide new insights into outcomes associated with different dialysis modalities. Only patients who have been under the care of a nephrologist and have planned for dialysis initiation will have dialysis access in place (whether a PD catheter or AVG/AVF), which makes comparisons between these groups reasonable. Furthermore, the use of a catheter versus AVG/AVG is known to be associated with higher infectious complications and higher mortality, and may bias toward worse early outcomes with HD, as suggested by prior observational studies. Thus, the analysis by Perl et al. appears to be a reasonable approach to compare outcomes between dialysis modalities while minimizing the inherent selection bias between groups.

However, cautious interpretation and application of these findings should be considered. This is a secondary analysis in which patients were allocated to one dialysis modality for a reason, whether it was patient or physician selection or other possibly unmeasured risk factors. While this study attempts to minimize these differences by minimizing pre-ESRD care as a confounder, residual unmeasured confounding likely exists. Despite over 50 years of
renal replacement therapy being federally funded in the United States, the ideal way to deliver dialysis and the best modality to use for individual patients remains uncertain. However, in the era of bundled payments, it has been proposed that the prevalence rates of PD will rise, as it remains a lower-cost therapeutic option. This study by Perl et al. supports the individualized use of PD as an equivalent dialysis modality to HD and as a preferred modality if the alternative is to start hemodialysis with a catheter.

DISCLOSURES

JKI receives support from the NIH (K23 HL092297) and investigator initiated grant support from Genzyme. RDT receives support from the NIH (K24DK002818) and grant support from Novartis and Reata Pharma.

REFERENCES


REIN on Obesity, Proteinuria and CKD

Mary E. Choi
Renal Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115


doi: 10.1681/ASN.2011040423

Chronic Kidney Disease (CKD) is a major public health concern worldwide and obesity is increasingly recognized as an independent risk factor for development of CKD. There has been a global epidemic of obesity and a parallel rise in the prevalence of metabolic syndrome that likely have contributed to the increasing incidence of CKD. Culprits implicated in this epidemic include the development of a general tendency toward sedentary lifestyles together with a diet with excessive caloric intake linked to junk food and high fructose consumption, largely in the form of high-fructose corn syrup in sugary sodas. Epidemiologic and experimental studies have linked high fructose intake with the development of obesity and metabolic syndrome, insulin-resistant diabetes, and albuminuria.

Obesity is associated with proteinuria and a more rapid progression of CKD and the reversal of obesity can improve proteinuria and GFR. Moreover, there is evidence that obesity causes glomerular hypertrophy and impaired glomerular function, even in the absence of a primary kidney disease. An obesity-related glomerulopathy akin to focal segmental glomerulosclerosis has been observed in morbidly obese patients, often accompanied by massive proteinuria and rapid loss of kidney function. Based on the high prevalence, associated complications, and rising cost, obesity that parallels an increase in the prevalence of CKD has become a global burden.

There is now convincing evidence for proteinuria as a marker of kidney injury and a surrogate outcome in CKD, and that reducing proteinuria can prevent or delay cardiovascular events and the progression of kidney disease. Blockers of the renin-angiotensin system (RAS) have emerged as the mainstay of therapy in large part due to their antiproteinuric effects in preventing the progression of kidney disease. Randomized trials assessing the efficacy of angiotensin-converting-enzyme (ACE) inhibitors with respect to kidney-protection have been studied in diabetic and as well as nondiabetic nephropathies. Notably, the Ramipril Efficacy In Nephropathy (REIN) study-1 was the first to demonstrate that an ACE inhibitor, ramipril, had a kidney-protective effect in slowing the decline of GFR in nondiabetic CKD patients with a proteinuria of 3 g or more per day.

In this issue, Mallamaci and colleagues, through a post hoc analysis of the REIN study cohort, asked two critical questions, whether body mass index (BMI) influences the incidence rate of renal events, defined as either doubling of serum creatinine or end-stage renal disease (ESRD), and whether obesity modifies the effect of ramipril on these outcomes. The latter question was not addressed previously. In the placebo-treated group, the incidence rate of renal outcomes was higher in obese patients than those with normal BMI. Importantly, treatment with ramipril not only reduced the incidence rate of renal


Published online ahead of print. Publication date available at www.jasn.org.

Correspondence: Mary E. Choi, M.D., Renal Division, Brigham and Women’s Hospital, Department of Medicine, Harvard Medical School, 4 Blackfan Circle, HLM-5, Boston, Massachusetts 02115, Phone: 617-525-5977, Fax: 617-525-5923, E-mail: mchoi@rics.bwh.harvard.edu

Copyright © 2011 by the American Society of Nephrology